Tiotropium as Asthma Add-On Treatment Shows Promise Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Spiriva Respimat (tiotropium bromide) inhalation spray for ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Once-daily tiotropium bromide as an add-on to inhaled corticosteroid therapy demonstrated ...

Please provide your email address to receive an email when new articles are posted on . Boehringer Ingelheim Pharmaceuticals announced that the FDA has agreed to review its new drug application for ...

BARCELONA, Spain — The risk for mortality in chronic obstructive pulmonary disease (COPD) patients being treated with tiotropium is the same whether the drug is delivered by the Respimat Soft Mist ...

The US Food and Drug Administration (FDA) yesterday approved an inhalation spray version of tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for maintenance treatment of chronic obstructive ...

SAN ANTONIO, Texas--(BUSINESS WIRE)--Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

Boehringer vigorously defended Respimat at the time, pointing out that the findings of the pooled data were flawed. Commenting on TIOSPIR, Richard Russell of the Wexham Park Hospital in the UK, said ...

LONDON & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance ...

Boehringer Ingelheim today announced new data analyses from the pivotal Phase III TONADO ® 1&2 studies 4 (NCT01431274/NCT01431287). Data showed tiotropium/olodaterol ...

Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance asthma therapy significantly improved lung ...